Markus McColly

594 citations
12 papers · 422 · 1 hit paper · h-index 5

Impact in

  • Genetics top 5%
    • Neurogenetic and Muscular Disorders Research
    • Virus-based gene therapy research
  • Molecular Biology
    • RNA modifications and cancer
    • Muscle Physiology and Disorders
    • CRISPR and Genetic Engineering
    • RNA Interference and Gene Delivery

Papers in

  • Genetics 11
    • Neurogenetic and Muscular Disorders Research 11
    • Genetics and Neurodevelopmental Disorders 1
  • Molecular Biology 8
    • RNA modifications and cancer 3
    • CRISPR and Genetic Engineering 3
    • Cancer-related gene regulation 2
    • RNA Interference and Gene Delivery 2
    • RNA and protein synthesis mechanisms 1
    • Muscle Physiology and Disorders 1
Co-authors
Lindsay N. Alfano (9 shared papers)Linda Lowes (8 shared papers)Samiah Al-Zaidy (5 shared papers)Kelly J. Lehman (8 shared papers)Richard Shell (8 shared papers)Jerry R. Mendell (7 shared papers)Matthew N. Meriggioli (4 shared papers)M. Iammarino (8 shared papers)
Journals
Neuromuscular Disorders (3 papers)Neurology (2 papers)Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (1 paper)Pediatric Neurology (1 paper)Journal of the Neurological Sciences (1 paper)
Partner nations
United StatesFrance

In The Last Decade

Markus McColly

11 papers receiving 415 citations

Markus McColly's Hit Papers

Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy 2021 · 181 citations
1810+1+3Years since publication50100150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2021 JAMA Neurology

Peers

Markus McColly
Comparison fields: 5 of 49
  • Genetics 255
  • Molecular Biology 225
  • Genetics 82
  • Surgery 108
  • Epidemiology 43
Replace Heike Kölbel with:
Heike Kölbel Germany
A. de Kleyn United States
Natalie F. Reash United States
Nicole Arrighi France
Ulrike Schara‐Schmidt Germany
Louise Deschênes Canada
Agata Robertson United Kingdom
Takahiro Yonekawa Japan
A. L. Delezoide France
Chiara Palka Italy
Markus McColly relative to Heike Kölbel Germany Heike Kölbel's profile →
Citations per field
00.5×1.5×2×2.5×
Heike Kölbel · 1×
Citations per year

Countries citing papers authored by Markus McColly

Since Specialization
Citations

This map shows the geographic impact of Markus McColly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus McColly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus McColly more than expected).

Fields of papers citing papers by Markus McColly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus McColly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus McColly. The network helps show where Markus McColly may publish in the future.

Co-authors

The 25 scholars most cited alongside Markus McColly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Markus McColly Line = papers co-authored together Markus McColly links everyone, so they are left out of the graph.

All Works

12 of 12 papers shown
#Work
1
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
JAMA Neurology ·Jerry R. Mendell, Samiah Al-Zaidy, Kelly J. Lehman, Markus McColly, Linda Lowes, Lindsay N. Alfano, Natalie F. Reash, M. Iammarino, Kathleen R. Church, A. de Kleyn, Matthew N. Meriggioli, Richard Shell
Hit paper breakdown →		2021181
2
Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy
Pediatric Neurology ·Linda Lowes, Lindsay N. Alfano, W. David Arnold, Richard Shell, Thomas W. Prior, Markus McColly, Kelly J. Lehman, Kathleen Church, Douglas M. Sproule, Sukumar Nagendran, Melissa Menier, Douglas E. Feltner, Courtney Wells, John T. Kissel, Samiah Al-Zaidy, Jerry R. Mendell
2019137
3
Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes
Molecular Therapy ·Jerry R. Mendell, Zarife Sahenk, Samiah Al-Zaidy, Louise R. Rodino‐Klapac, Linda Lowes, Lindsay N. Alfano, Katherine Berry, N. Miller, Mehmet E. Yalvaç, Igor Dvorchik, Melissa Moore‐Clingenpeel, Kevin M. Flanigan, Kathleen Church, Kim Shontz, Choumpree Curry, Sarah Lewis, Markus McColly, Mark Hogan, Brian K. Kaspar
201781
4
AVXS-101 Gene-Replacement Therapy (GRT) in Spinal Muscular Atrophy Type 1 (SMA1): Long-Term Follow-Up From the Phase 1 Clinical Trial (S25.006)
Neurology ·Jerry R. Mendell, Kelly J. Lehman, Markus McColly, Linda Lowes, Lindsay N. Alfano, N. Miller, M. Iammarino, Kathleen Church, Francis G. Ogrinc, James L’Italien, Courtney Wells, Douglas M. Sproule, Douglas E. Feltner
20196
5
Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): Long-term follow-up from the onasemnogene abeparvovec phase 1/2A clinical trial
Journal of the Neurological Sciences ·Jerry R. Mendell, Richard Shell, Kelly J. Lehman, Markus McColly, Linda Lowes, Lindsay N. Alfano, N. Miller, M. Iammarino, K. Church, Sidney A. Spector, Francis G. Ogrinc, Haojun Ouyang, Elaine Kernbauer, S. Shah, James L’Italien, D.M. Sproule, Douglas E. Feltner, S. Al-Zaidy
20194
6
SMA – THERAPY
Neuromuscular Disorders ·Jerry R. Mendell, Richard Shell, Kelly J. Lehman, Markus McColly, L. Lowes, L. Alfano, N. Miller, M. Iammarino, K. Church, Francis G. Ogrinc, Haojun Ouyang, Elaine Kernbauer, S. Joshi, Douglas M. Sproule, Matthew N. Meriggioli, Douglas E. Feltner, S. Al-Zaidy
20203
7
Gene-Replacement Therapy in Spinal Muscular Atrophy Type 1: Long-Term Follow-Up From the Onasemnogene Abeparvovec-xioi Phase 1/2a Clinical Trial (1808)
Neurology ·Jerry R. Mendell, Richard Shell, Kelly J. Lehman, Markus McColly, Linda Lowes, Lindsay N. Alfano, N. Miller, M. Iammarino, Kathleen Church, Francis G. Ogrinc, Haojun Ouyang, Elaine Kernbauer, Shivani Joshi, Douglas M. Sproule, Matthew N. Meriggioli, Douglas E. Feltner, Samiah Al-Zaidy
20203
8
P.066 AVXS-101 gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the phase 1 clinical trial
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ·JR Mendell, KJ Lehman, Markus McColly, L. Lowes, L. Alfano, NF Miller, MA Iammarino, K. Church, M. Schultz, FG Ogrinc, James L’Italien, Elaine Kernbauer, Sunil Shah, D.M. Sproule, DE Feltner
20192
9
Gene-Replacement Therapy (GRT) in Spinal Muscular Atrophy Type 1 (SMA1): Long-Term Follow-Up From the Onasemnogene Abeparvovec Phase 1/2 Clinical Trial
Neuropediatrics ·Jerry R. Mendell, Richard Shell, Kelly J. Lehman, Markus McColly, Linda Lowes, Lindsay N. Alfano, N. Miller, M. Iammarino, Kathleen Church, Uwe Ernst, Francis G. Ogrinc, Haojun Ouyang, Elaine Kernbauer, Shivani Shah, James L’Italien, Douglas M. Sproule, Douglas E. Feltner, Samiah Al-Zaidy
20192
10
S11 Long-term follow-up of the phase 1 START trial of onasemnogene abeparvovec gene therapy in spinal muscular atrophy type 1
JR Mendell, Richard Shell, KJ Lehman, Markus McColly, L. Lowes, L. Alfano, NF Miller, MA Iammarino, K. Church, Imran Kausar, S. Reyna, Matthew N. Meriggioli, A. de Kleyn, S. Al-Zaidy
20212
11
P.351Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the onasemnogene abeparvovec phase 1/2a clinical trial
Neuromuscular Disorders ·J. Mendell, Richard Shell, Kelly J. Lehman, Markus McColly, L. Lowes, Lindsay N. Alfano, N. Miller, M. Iammarino, K. Church, Francis G. Ogrinc, Haojun Ouyang, Elaine Kernbauer, Sunil Shah, James L’Italien, D.M. Sproule, DE Feltner, S. Al-Zaidy
20191
12
P.214Presymptomatic spinal muscular atrophy: reality or myth?
Neuromuscular Disorders ·Linda Lowes, Lindsay N. Alfano, D. Chen, Leslie Nelson, N. Miller, M. Iammarino, Markus McColly, J. Mendell, Steven W. Rust
20190

About Markus McColly

Markus McColly is a scholar working on Genetics, Molecular Biology, Epidemiology, Cell Biology and Genetics, having authored 12 papers that have together received 422 indexed citations. Recurring topics across this work include Neurogenetic and Muscular Disorders Research (11 papers), RNA modifications and cancer (3 papers), CRISPR and Genetic Engineering (3 papers), Cancer-related gene regulation (2 papers), RNA Interference and Gene Delivery (2 papers), RNA and protein synthesis mechanisms (1 paper), Genetics and Neurodevelopmental Disorders (1 paper) and Muscle Physiology and Disorders (1 paper). The work is most often cited by research in Genetics (255 citations), Molecular Biology (225 citations), Genetics (82 citations), Surgery (108 citations) and Epidemiology (43 citations). Markus McColly has collaborated with scholars based in United States and France. Frequent co-authors include Lindsay N. Alfano, Linda Lowes, Samiah Al-Zaidy, Kelly J. Lehman, Richard Shell, Jerry R. Mendell, Matthew N. Meriggioli, M. Iammarino, A. de Kleyn and Natalie F. Reash. Their work appears in journals such as Neuromuscular Disorders, Neurology, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, Pediatric Neurology and Journal of the Neurological Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heike KölbelBreakdown of academic impact, for papers by A. de KleynBreakdown of academic impact, for papers by Natalie F. ReashBreakdown of academic impact, for papers by Nicole ArrighiBreakdown of academic impact, for papers by Ulrike Schara‐SchmidtBreakdown of academic impact, for papers by Louise DeschênesBreakdown of academic impact, for papers by Agata RobertsonBreakdown of academic impact, for papers by Takahiro YonekawaBreakdown of academic impact, for papers by A. L. DelezoideBreakdown of academic impact, for papers by Chiara Palka